5月16日 - ** 券商瑞银将制药商Iovance Biotherapeutics IOVA.O的评级从 "买入 "下调至 "中性"，将目标价从17美元下调至2美元
** 新的PT仍意味着该股较上次收盘价有13.6%的上涨空间
** Iovance 公司皮肤癌药物Amtagvi在2025年第一季度的销售额低于预期，全年业绩预期也因增长速度低于预期而下调。
** 瑞银认为，增长放缓的原因是实施问题、医院基础设施不足、资源有限以及报销障碍。
** 25 年第一季度较高的退出率似乎表明患者选择并非最佳，可能需要对医生进行更多教育"--瑞银集团
** 包括本交易日的走势在内，IOVA 的股价今年累计下跌 77.4
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.